This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novavax (NVAX) COVID Jab Receives EU Nod for Adolescents
by Zacks Equity Research
Novavax (NVAX) obtains EU approval for its Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17.
Can Moderna (MRNA) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights Pfizer, BioNTec and Moderna
by Zacks Equity Research
Pfizer, BioNTec and Moderna are part of Zacks Analyst top Blog.
FDA Recommends Adding New Omicron Subvariants to COVID Boosters
by Sundeep Ganoria
In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.
Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.
The Chef's Warehouse and AZEK have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
The Chef's Warehouse and AZEK are part of as Zacks Bull and Bear of the Day article.
FDA Panel Recommends Modifying COVID Jabs to Target Omicron
by Kinjel Shah
The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $145.36, marking a +0.76% move from the previous day.
Pfizer's (PFE) Omicron-Based COVID Shot Betters Immune Response
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.
Novavax (NVAX) Up as EMA Recommends COVID Jab for Adolescents
by Zacks Equity Research
EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
by Kinjel Shah
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
Moderna (MRNA) Reveals New Data on Bivalent COVID Booster
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.
Company News for Jun 23, 2022
by Zacks Equity Research
Companies in The News Are: MRNA, KFY, XOM, WGO
Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More
by Zacks Equity Research
Regulatory and other updates from Moderna (MRNA) and Acer (ACER) are a few key highlights from the biotech sector during the past week.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $129.99, marking a +1.53% move from the previous day.
FDA Authorizes PFE & MRNA's COVID Jabs for 6 Months & Older Kids
by Zacks Equity Research
FDA authorizes Pfizer (PFE) and BioNTech's Comirnaty for use in children aged six months through four years. Moderna's (MRNA) Spikevax gains EUA for use in individuals aged 6 months through 17 years.
The Zacks Analyst Blog Highlights Lilly, Merck, Roche, Pfizer and Moderna
by Zacks Equity Research
Lilly, Merck, Roche, Pfizer and Moderna have been included in this Analyst Blog.
Pharma Stock Roundup: FDA Panel Nod for PFE, MRNA Young Kids' COVID Jabs & More
by Kinjel Shah
FDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.
Oxford Industries and Flagstar Bancorp have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Oxford Industries and Flagstar Bancorp have been highlighted as Zacks Bull and Bear of the Day.
FDA Panel Recommends Pfizer & Moderna COVID Jabs for Young Kids
by Kinjel Shah
The FDA VRBPAC committee unanimously recommends the approval of both Pfizer and BioNTech and Moderna's vaccines for young children, saying the benefits of the vaccines outweigh the risks.
Pfizer (PFE) Starts EU Submission of Variant-Adapted Vaccine
by Zacks Equity Research
Pfizer (PFE) and its partner BioNTech initiate rolling submission, seeking authorization of the variant-adapted version of their COVID-19 vaccine.
Moderna's (MRNA) COVID-19 Vaccine Nears EUA in Pediatrics
by Zacks Equity Research
An FDA advisory committee voted in favor of the use of Moderna's (MRNA) COVID-19 vaccine in individuals aged 6 years to 17 years. A meeting to discuss the use of the vaccine in the younger population is scheduled for today.
Pfizer, BioNTech's COVID Jab Safe in Young Kids Per FDA
by Zacks Equity Research
Per the FDA reviewers, the available data supports Pfizer (PFE) and BioNTech (BNTX) vaccine's effectiveness in preventing COVID infection in kids six months to under five years of age as a three-dose primary series.
Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.
Why Is Exelixis (EXEL) Down 3.1% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.